{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hong S"],"funding":["Celgene","GlaxoSmithKline","Actinium Pharmaceuticals","Janssen/Johnson &amp; Johnson","NHLBI NIH HHS","National Heart, Lung, and Blood Institute","Pharmacyclics, LLC","Terumo BCT","Adienne SA","National Institutes of Health","Legend Biotech","Adaptive Biotechnologies","Novartis Pharmaceuticals Corporation","CSL Behring","Magenta Therapeutics","CytoSen Therapeutics","AstraZeneca","Kyowa Kirin","NIH HHS","Janssen Pharmaceuticals","Mallinckrodt LLC","Bristol-Myers Squibb","Medac GmbH","Merck Sharp &amp; Dohme Corp","NIAID NIH HHS","Orca Biosystems, Inc","Medical College of Wisconsin","Millennium (the Takeda Oncology Co)","Merck &amp; Company, Inc","Gamida-Cell","Viracor Eurofins","Health Resources and Services Administration (HRSA)","Jazz Pharmaceuticals","Daiichi Sankyo Co","Genzyme","Mesoblast","Atara Biotherapeutics","Takeda Pharmaceuticals U.S.A.","Amgen","Takeda Pharma","Kite Pharma","Anthem","Incyte Corporation","Merck","Novartis Oncology","Kiadis Pharma","Chimerix","REGiMMUNE Corp","AlloVir","Sanofi Genzyme","Xenikos BV","National Cancer Institute","Seattle Genetics","Takeda Oncology","Merck Sharp and Dohme","The National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID)","Pfizer","Bluebird Bio","Daiichi-Sankyo","Health Resources and Services Administration","AbbVie","HistoGenetics","Office of Naval Research","Regeneron Pharmaceuticals","Janssen Biotech","Miltenyi Biotec","Kyowa Hakko Kirin","Astellas Pharma US","Omeros Corporation","NCI NIH HHS","Sobi, Inc","OncoImmune, Inc"],"pagination":["609-618"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7855526"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["127(4)"],"pubmed_abstract":["<h4>Background</h4>The association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.<h4>Methods</h4>This study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated l"],"journal":["Cancer"],"pubmed_title":["Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States."],"pmcid":["PMC7855526"],"funding_grant_id":["R01 HL131731","R01 HL130388","R01 HL129472","N00014‐20‐1‐2705","N00014-18-1-2850","N00014‐18‐1‐2850","R01‐CA215134","SC1MC31881‐01‐00","U01HL128568","U01 HL128568","R21 HL140314","U24 HL138660","N00014-20-1-2705","R01 HL126589","HHSH250201700007C","N00014‐18‐1‐2888","N00014-18-1-2888","R01 CA152108","R01 CA215134","R01 AI128775","R01 CA218285","U01 AI069197","U01 CA246659","R01 CA231141","R21HL140314","K23 HL150232","U01 AI126612","P30 CA016672","U24 CA076518","HHSH250201700006C","U24CA076518","SC1MC31881-01-00","P01 CA111412"],"pubmed_authors":["Ulrickson M","Szwajcer D","Ganguly S","Yared JA","Hashmi S","Hashem H","Abdel-Azim H","Khera N","Rizzo JD","Badawy SM","Olsson RF","Aljurf MDSM","Wood WA","Beattie S","Sharma A","Schoemans H","Gratwohl AA","Beitinjaneh AM","Majhail NS","Ciurea SO","Rizzieri D","Kamble RT","Lazarus H","Lee SJ","Saber W","Hebert KM","Farhadfar N","Law J","Cerny J","Seo S","Shaw BE","Diaz MA","Brazauskas R","Yoshimi A","Hahn T","Bhatt NS","LeMaistre C","Gergis U","Savani BN","Hong S"],"additional_accession":[]},"is_claimable":false,"name":"Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.","description":"<h4>Background</h4>The association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.<h4>Methods</h4>This study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated l","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Feb","modification":"2026-06-02T21:51:43.269Z","creation":"2025-06-01T01:33:11.27Z"},"accession":"S-EPMC7855526","cross_references":{"pubmed":["33085090"],"doi":["10.1002/cncr.33232"]}}